PolyPid Ltd reports results for the quarter ended December 31 - Earnings Summary

Polypid

12/02/2025 14:32

* PolyPid Ltd  PYPD.OQ  reported a quarterly adjusted loss
of
$1.09​​ per share for the quarter ended December 31, higher than
the same quarter last year, when the company reported EPS of
$-3.97.  The mean expectation of four analysts for the quarter
was for a loss of 88 cents per share. Wall Street expected
results to range from $-1.04 to -71 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * PolyPid Ltd's reported EPS for the quarter was a loss of
$1.09​.
    * The company reported a quarterly loss of $8.52 million.
    * PolyPid Ltd shares had fallen by 5.1% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 19.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for PolyPid Ltd is
$10.50 
This summary was machine generated from LSEG data February 12 at
02:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.88          -1.09          Missed
 Sep. 30 2024      -1.00          -1.22          Missed
 Jun. 30 2024      -1.30          -1.25          Beat
 Mar. 31 2024      -1.41          -1.37          Beat